Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Patients across Michigan — from Adrian to communities throughout the state — are losing weight with FDA-approved peptide medications through licensed telehealth. A custom peptide plan goes beyond a generic prescription: your physician evaluates your unique metabolic profile, selects the right peptide medication, and builds a dosing schedule calibrated specifically to your body. MI-licensed physicians guide every step.
The peptide medications used in custom plans — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are bioactive GLP-1 receptor agonists rigorously studied in large clinical trials. Semaglutide produced 15%% average weight reduction in the STEP trials. Tirzepatide achieved 22.5%% in the SURMOUNT trials. Custom plans ensure you follow the evidence-based approach that produced these outcomes.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
Michigan patients receive their custom peptide plans entirely online — no clinic visits required. All physicians hold active MI medical licenses and personalize every plan based on your individual health assessment. Your custom plan begins with a comprehensive evaluation and includes scheduled monitoring check-ins throughout your treatment.
Select your Michigan city to get your personalized peptide weight loss plan. Licensed physicians are serving patients across the entire state.
Three randomized controlled trials published in the New England Journal of Medicine establish the evidence base for FDA-approved GLP-1 medications:
Michigan authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in Michigan.
Personalized peptide weight loss plans are available beyond Michigan — custom plans are accessible in all neighboring states and all 50 states nationwide.
Personalized peptide weight loss plans are available in the largest cities across the United States.
Local weight loss and GLP-1 providers serving the Michigan area, based on Google Business listings.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Michigan patients on custom peptide plans have access to semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — all FDA-approved peptide receptor agonists. Your MI-licensed physician selects the optimal agent based on your individual health profile, metabolic goals, and existing conditions.
Most Michigan custom plan patients notice appetite reduction within the first 1-2 weeks. Measurable weight reduction typically begins in weeks 2-4 and accelerates through months 3-6 as the personalized dose escalation progresses. Results vary based on each patient's individual plan and metabolic response.
Yes. Custom peptide plans are available to patients throughout all of Michigan through licensed telehealth. All prescribing physicians hold active MI state medical licenses. Whether you are in a major city or a smaller community, your personalized plan is fully accessible online.
A custom plan is designed specifically for your body — your starting dose, your titration timeline, your monitoring checkpoints. Standard prescriptions apply a generic schedule that may not match your individual tolerance or metabolic needs. Custom plans also include built-in adjustment mechanisms: if your body responds differently than expected, your physician updates the plan accordingly.
The initial custom peptide plan for Michigan patients is typically designed around 68-72 weeks — consistent with the duration of the landmark clinical trials. After completing the initial plan, MI physicians work with patients on personalized maintenance strategies to preserve results long-term.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
